T Aatif 1 , R Akka2 , and M Sbaai3
1Department of Nephrology and Hemodialysis, 5th Military Hospital, Guelmim, Mohammed V University, Morocco 2Department of Gastroenterology, 5th Military Hospital, Morocco 3Laboratory of Bio safety P3, 5th Military Hospital, MoroccoFulltext PDF
Introduction: Direct-Acting Antiviral agents (DAAs) have revolutionized the treatment of chronic Hepatitis C Virus (HCV) with Sustained Viral Response (SVR) achievable in more than 90% of all patients with few side-effects. This treatment is required to decrease the significant morbidity and mortality impact of the disease worldwide. We report a successful full dose sofosbuvir and daclatasvir treatment of HCV Infection in a patient with severe renal insufficiency. Case Presentation: A 77-year-old male with a history of Chronic Kidney Disease (CKD) stage 4 was referred to our hospital for chronic HCV. The patient was treated by a combination of full dose sofosbuvir and daclatasvir without adverse effects or interaction between this regimen and other medications used by the patient. The patient’s HCV load was undetectable at week 4, 8, 12 and a SVR was confirmed at week 48 post-treatment consistent with eradication of infection. Conclusion: This report highlighted the effectiveness and safety of the association of sofosbuvir and daclatasvir to treat HCV in the elderly with severe CKD.
Hepatitis C virus; Direct-acting antiviral; Chronic kidney disease; Elderly
T Aatif, R Akka, M Sbaai. Full-Dose Sofosbuvir and Daclatasvir to Treat Hepatitis C Virus Infection in a 77- Year-Old Patient with Severe Renal Insufficiency. Ann Clin Case Rep. 2020; 5: 1841. ISSN: 2474-1655.